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a  b  s  t  r  a  c  t
Coronary  rupture  during  cardiac  catheterization  and  angioplasty  is  an uncommon  but serious  complica-
tion.  Predisposing  factors  to  this  dreadful  complication  are  not  well  deﬁned.  We present  a  case  of  coronary
artery  rupture  during  an  urgent  percutaneous  intervention  in  a patient  under  chronic  immunosuppres-ccepted 19 July 2012
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ntravascular ultrasound
sive  therapy  with  corticosteroids  and  azathioprine,  despite  intravascular  ultrasound  (IVUS)  guidance.
Initially,  the perforation  was  successfully  managed  with  balloon  inﬂation  and  ﬁnally,  a covered  stent
was  deployed  at the  site.  The  unexpected  rupture,  despite  optimal  IVUS  sizing,  indicates  a  possible  role
of  immunosuppressive  therapy  in coronary  artery  wall vulnerability.  Extra  caution  should  be  exerted  in
such  patients  while  performing  coronary  interventions  and  using  intracoronary  devices.
© 2012  Japanese  College  of  Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.ntroduction
Coronary rupture during cardiac catheterization and angio-
lasty is an uncommon but serious complication occurring in
.2–3% of interventional procedures [1]. When coronary perfora-
ion occurs, it may  rapidly result in cardiac tamponade, myocardial
nfarction, or death, hence prompt treatment is required. Ther-
peutic measures include reversal of heparin, prolonged balloon
nﬂation at the perforation site, deployment of a covered stent, or
mergency cardiac surgery.
Despite the importance of this dreadful complication, there are
imited data on factors that may  predispose to coronary arterial
all rupture. Indeed, the impact of speciﬁc medications or dis-
ases on vascular susceptibility, by weakening coronary arterial
all, through direct or indirect impact on the function of smooth
uscle cells, ﬁbroblasts, and endothelium, is not known.
We  report a case of coronary artery rupture during urgent per-
utaneous coronary intervention in left main (LM), left anterior
escending (LAD) and circumﬂex (LCX) arteries, despite intracoro-
ary ultrasound (IVUS) guidance for vessel sizing, in a patient
eceiving chronic immunosuppressive treatment (corticosteroid
nd azathioprine).
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878-5409/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jccase.2012.07.006Case report
A  49-year-old man  (175 cm height, 90 kg weight, BMI: 29.5)
with a 10-year history of autoimmune hepatitis (type I), pul-
monary ﬁbrosis, and pulmonary hypertension, was  transferred to
our hospital due to unstable angina. He was  under medication with
prednisone 10 mg  and azathioprine 50 mg  per day for the previous
10 years. His coronary risk factor proﬁle included smoking and high
blood glucose levels due to chronic therapy with corticosteroids.
Three  years ago, the patient had undergone coronary angiog-
raphy for stable angina pectoris. At that time, he had severe right
coronary artery (RCA) stenosis and was treated with a 3.0/18 mm
Endeavor Resolute drug-eluting stent (Medtronic, Minneapolis,
MN, USA), while the rest of the coronary arteries had atherosclerotic
lesions of less than 50%. Six months previously he had undergone
a new coronary angiography for similar symptoms, which showed
a stenosis of 40% at the distal LM and a diffusely disease and nar-
row LAD with tightest stenosis at the proximal and mid  segment
(75–80%). The LCX artery had a signiﬁcant long lesion (80% stenosis)
at the proximal segment, while RCA had a non-signiﬁcant steno-
sis 30–40% at the mid  segment. His left ventricle ejection fraction
was measured by echocardiography at 40%. Coronary artery bypass
grafting (CABG) was  considered to be the most suitable treatment
option. However, due to the patient’s comorbidities (pulmonary
ﬁbrosis and autoimmune hepatitis), he was  rejected for CABG and
was scheduled for elective percutaneous coronary intervention
(PCI).
vier Ltd. All rights reserved.
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However, due to the development of unstable angina while on
he waiting period, he was transferred to our clinic for urgent PCI.
he whole procedure was guided by IVUS due to the complexity of
he procedure.
The intervention was performed via the left femoral artery using
 6 French Z2 EBU 3.5 guiding catheter (Medtronic). Ten thousand
nits of heparin (weight-adjusted at 70 U/kg) were given at the
eginning of the procedure with a further 4000 units after 60 min
o keep the activated clotting time (ACT) >250 s.
A BMW  wire (Abbott Vascular, Abbott Park, IL, USA) was  passed
own the LAD and angiographic measurements and IVUS exami-
ation were performed (Fig. 1). LAD angiography revealed a 75%
tenosis in the distal segment, a 75% stenosis in the mid segment,
nd a 70% stenosis in the proximal. Subsequently an 80% steno-
is was found in the proximal LCX, while ﬁnally a 50% lesion was
evealed in the distal LM.  The corresponding quantitative coronary
nalysis (QCA) measured diameters at the LAD stenotic sites seg-
ents from distal to proximal were 0.6 mm,  0.65 mm,  and 0.7 mm
espectively with vessel reference 2.4 mm.  Similarly, for LCX the
roximal segment diameter was 0.5 mm  (reference vessel: 2.2 mm)
nd for distal LM stenosis diameter was measured 1.6 mm (refer-
nce vessel: 3 mm).
IVUS examination did not reveal any intense calciﬁcation in the
therosclerotic plaque of the displayed segments. In particular, it
howed at point C (Fig. 1) a concentric plaque, which contained mild
brotic areas, but mostly, similar echogenicity with the adventitia.
ross sectional image B (Fig. 1) shows an eccentric atherosclerotic
laque with negative remodeling without intense calciﬁcation but
ith spotty echogenic areas within the plaque probably represent-
ng ﬁbrocalciﬁc components. Finally, LM cross sectional image A
Fig. 1) shows an eccentric soft plaque with mild ﬁbrocalciﬁc tissues
n less than one quarter of circumference. In none of the ﬁbrocalciﬁc
egments, reverberation or acoustic shadowing was  observed.
The  stent expansion in the LM and LAD was guided by the IVUS
atheter (Eagle Eye, Volcano Corp, Rancho Cordova, CA, USA), per-
itting the exact measurement of the vessels’ diameter and the
se of the appropriate stent dimension. Balloon dilations were per-
ormed with Maverick Monorail balloons (Boston Scientiﬁc, Natick,
A,  USA), while the drug eluting stents (DES) used, were Cipher
Cordis, Johnson and Johnson, Miami  Lakes, FL, USA) and Taxus®
Boston Scientiﬁc), left at the discretion of the main operator.
Initially,  predilation with a 2.75/20 mm and a 2.0/20 mm Maver-
ck Monorail balloon was performed. Two Cipher stents were then
eployed from distal to mid  vessel: 2.25/33 mm and 2.75/33 mm,
espectively. Subsequently, we intervened upon the proximal LAD
tenosis, implanting a 3.5/23 mm paclitaxel-eluting stent (Taxus®,
oston Scientiﬁc), according to the IVUS measurements (minimum
essel diameter 4.7 mm)  (Fig. 1C).
We  treated next the stenosis in the proximal LCX with the
eployment of a 2.75/33 mm Cipher® stent, using the T-Stenting
nd small Protrusion technique (TAP-technique). According to this
ovel modiﬁcation of T-stenting technique, after stenting of the
ain vessel, a minimal protrusion of the side-branch stent within
he main vessel is intentionally left, before ﬁnal kissing balloon is
erformed [2].
Afterward, the distal section of the LM was treated. We  per-
ormed predilation with a 3.5/20 mm Maverick Monorail balloon
nd then we deployed a 4/12 mm Taxus® stent spanning from the
id LM until the oriﬁce of the LAD, treating at the same time
he stenotic segments of the distal LM (minimum vessel diame-
er 4.9 mm)  (Fig. 1A) and the very proximal LAD (minimum vessel
iameter 4 mm)  (Fig. 1B). According to the IVUS measurement, in
rder to achieve the best possible stent apposition and stenosis
estoral, we performed postdilation at that site, with a 4.0/20 mm
ercury NC non-compliant balloon (Abbott Vascular) at 16 atmo-
pheres (atm). Immediately after that inﬂation, a rupture of theology Cases 6 (2012) e145–e149
proximal  LAD vessel wall, already covered with stent, was  caused,
resulting in an Ellis Class II perforation [1] with localized extrava-
sation of contrast (Fig. 2A). This was  accompanied by ischemia of
the area supplied by the LAD with development of electrocardio-
graphic changes (ST anterior elevation) and severe angina pectoris.
Immediately, a 3.5/12 mm Maverick balloon was  rapidly delivered
at the perforation site and inﬂated initially at 6 atm for 3 min  result-
ing in sealing the leakage, probably as a result of mechanical stress
opposed to the arterial wall, facilitating development of throm-
bus. After ensuring the sealing with multiple effusions, the IVUS
catheter was used again in order to record the rupture and investi-
gate the possible mechanisms resulting to it (Fig. 2B).
Subsequently, a LM proximal segment deterioration was noted
and a 4.5/20 mm Taxus® stent was  deployed at the aortic ostia,
overlapping with the stent already deployed distally.
Finally, it was decided to deploy a 3/18 mm Over and Under®
equine pericardium-covered stent (ITGI Medical Ltd., Or Akiva,
Israel) in order to secure the sealing of the ruptured vessel. The IVUS
catheter was used again conﬁrming the appropriate expansion of
the stents and the effective sealing (Fig. 3A–C).
The ECG changes and the symptoms subsided and the
patient was transferred to the intensive care unit. A small
hemopericardium developed without deterioration of the patient’s
hemodynamic state. He remained in stable condition without reap-
pearance of angina symptoms. Measured troponin I was repeatedly
found within normal limits. The amount of pericardial effusion
diminished gradually in the following days. The patient was dis-
charged on the seventh post-procedural day. Four months later, he
was in good condition and had no episodes of angina.
Discussion
Although acute coronary rupture is infrequent, it is not rare,
and it can be associated with signiﬁcant morbidity and mortality
[3]. In previous studies, women  and the elderly have been found
to be at particular risk of this complication [1]. Perforation during
angioplasty is usually caused by guide wire trauma, balloon rup-
ture, balloon or stent oversizing [1]. The continuously increasing
use of intracoronary devices enhances the risk of a possible dam-
age and rupture of the vessel wall [1]. When such complications
occur, promising results have been obtained with the use of cov-
ered stents, like in our patient, with sealing of the perforation in
the vast majority of cases [4]. Alternatively, emergency coronary
artery bypass is mandatory but this procedure is still associated
with signiﬁcant hospital mortality [1].
Multiple studies in patients under immunosuppressive therapy
(post-orthotopic heart-kidney transplantation) have shown pro-
gression of coronary artery disease (CAD) [6]. We cannot exclude
the possibility that immunosuppressive therapy contributed to the
progression of CAD during the previous three years in addition
to the presence of common coronary risk factors present in our
patient. Indeed, he was under dual immunosuppressive medication
with corticosteroids and azathioprine due to autoimmune hepati-
tis for a long period, while additionally, he had abnormal glucose
levels and was  a smoker.
An  unexpected perforation occurred in our case despite all pos-
sible precautions that were taken. Firstly, due to the diffuse nature
of the coronary atherosclerosis, the procedure, as far as vessel
sizing and selection of balloons and stents, relied mainly on IVUS
measurements. It is well known that diffuse disease, as was the
care for the proximal LAD, is better treated with IVUS guided inter-
vention. Indeed, what we observed in sequence A, B and C (Fig. 1)
is the absence of a normal reference segment up to the point of the
origin of the ﬁrst diagonal. In addition, image B corresponding to
the proximal LAD, shows a rather eccentric plaque with probable
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dig. 1. Left coronary artery angiography before intervention; gray scale intravascul
escending artery (LAD) stenotic segment, and (C) positive remodeling on proxima
egative remodeling compared to image C, corresponding to a
ore distal point. However, the absence of a normal segment
akes this assessment rather speculative. We  have shown that
his process is common in diabetic patients and probably was
elated to the abnormal glucose levels observed in our patient [5].
owever, even at the site of “negative” remodeling, vessel diame-
er remained above 4 mm.  Besides, the sizing of the non-compliant
alloon (4.0 mm)  and the diameter of the stent (3.5 mm proximal
AD, 4.0 mm LM-LAD), were smaller than the estimated LAD
iameters by IVUS (max 4.5 mm,  min  4.0 mm,  average 4.2 mm).
Fig. 2. Left anterior descending artery, Ellis Class II, perforation (arrows): (Aasound demonstrating: (A) left main artery stenosis, (B) very proximal left anterior
segment.
There is not any doubt that calciﬁcation is a risk factor for dissec-
tion and perforation during high pressure balloon inﬂation during
coronary angioplasty. In order to avoid these complications a thor-
ough examination of the LM and LAD artery was  performed. In
distal LM (Fig. 1A), an eccentric plaque with some ﬁbrotic tissue,
but mostly soft, was observed from 6 to 3 o’clock circumference.
In proximal LAD (Fig. 1B), there is an eccentric plaque with more
dense tissue, probably some ﬁbrocalciﬁc components, but without
reverberations or acoustic shadowing. In distal LAD there is a con-
centric plaque with spotty ﬁbrocalciﬁc regions deep in the border
) ﬂuoroscopic angiogram, and (B) grayscale intravascular ultrasound.
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Fig. 3. Final left coronary artery angiography after covered stent deployment: (A) right anterior oblique caudal view, (B) spider view, and (C) gray scale intravascular
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tltrasound demonstration of the deployed covered stent (yellow arrow) within the
ith adventitia. Although calciﬁcation is present, it cannot be con-
idered as severe to the point to justify the use of other modality
or lesion modiﬁcation before stenting, such as rotablator or cutting
alloon.
Therefore, the unexpected perforation despite optimal sizing,
ndicated the presence of a factor contributing to the coronary arte-
ial wall vulnerability and rupture. Indeed, corticosteroids are well
nown to have a severe negative effect on collagen formation, con-
ective tissue strength and wound healing [6]. Moreover, in the
reas of inﬂammation, such as the atherosclerotic plaque, corti-
osteroids seem to affect ﬁbroblasts in a way of producing less
ollagen and ground substance [6]. Besides, studies have shown
hat chronic use of corticosteroids results in vasomotor dysfunc-
ion and vascular injury. The mechanisms for these actions include
irect oxidant injury, increased cytokine release and altered reg-
lation of endothelial nitric oxide production [7]. In general, in
he vascular endothelium, corticosteroids have been proven to
uppress the production of vasodilators such as prostacyclin and
O, while similar effects have been also shown in coronary artery
ndothelium [7]. Our hypothesis of possible corticosteroid-related
ascular wall vulnerability is enhanced by several studies indicat-
ng that corticosteroids modulate vascular smooth muscle cells
henotype by inhibiting their proliferation [8]. Based on the fact
hat arterial intima and media wall layers comprise smooth mus-
le cells contributing to artery elasticity and strength, it can be
ssumed that corticosteroids’ chronic action could affect vessel
all durability. The aforementioned data point to the direction
hat use of corticosteroids may  result in vessel wall weakness and
ncreased susceptibility to rupture under balloon inﬂation at high
tmosphere.
Azathioprine, the second immunosuppressive factor taken by
ur patient, has not been proven to have a direct damaging effect
o coronary artery wall. Small studies only, implicate a possiblemm drug-eluting stent (red arrow) at the perforation site.
impact  of combined immunosuppressive treatment, including aza-
thioprine, on early graft coronary endothelial injury after heart
transplantation [9]. However, we  cannot exclude the possibility of
smooth muscle cells and ground substance dysfunction because of
the dual immunosuppressive treatment.
Furthermore, the impact of an autoimmune disease and the
coexisting autoimmune inﬂammatory process on coronary artery
disease cannot be underestimated. It has been shown that lupus
erythematosus has been associated with endothelial dysfunction
[10].
It is obvious that images provided by IVUS cannot provide infor-
mation regarding the histological changes observed in cellular
and matrix level that may  have occurred by immunosuppressive
therapy.  Ideally, new techniques, such as optical coherence tomog-
raphy, virtual histology, or near-infrared spectroscopy could have
provided more information. However, due to the emergency of the
patient’s situation, these techniques were not able to be performed.
In addition, our report indicates that there are no speciﬁc micro-
structural differences that could be detected and alert for the risk
for this dreadful complication, just by interpreting IVUS imaging.
Despite  the initial sealing of the leakage with balloon inﬂation,
we proceeded to the deployment of the covered stent at the area
of vessel rupture. We  believe that the covered stent deployment
minimizes the possibility of reoccurrence of leakage and ensures
the therapeutic outcome in a patient with vascular susceptibility.
Furthermore, the combination of patient medication (corticoste-
roid plus azathioprine) may  interfere with the healing process of
the ruptured wall.
The  over and under covered stent used in our case, is a
highly ﬂexible laser-cut single stainless steel stent that is covered
with processed biocompatible equine pericardium. This structure
makes the device less bulky and more ﬂexible than the PTFE-
covered stents, which consist of a balloon-expandable layer of PTFE
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andwiched between two stainless steel stents. These advantages
mply superior and less damaging deliverability in demanding
esions of high risk, like in our case.
In conclusion, for this patient, chronic treatment with corticos-
eroids and azathioprine might have been a contributing factor in
he creation of coronary rupture despite the guidance by IVUS. In
uch patients, extra caution should be exerted because of possi-
le underlying vessel weakness and invasive cardiologists should
e extremely careful in the use of intracoronary devices and post-
tenting inﬂation at high pressures.
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